Abstract
BackgroundChronic HCV infection is a global health problem causing progressive hepatic fibrosis, cirrhosis, and ultimately hepatocellular carcinoma (HCC). Recent advantage of direct-acting antiviral drugs (DAA) with a high sustained virologic response (SVR) reduces overall HCV-related morbidity and mortality, yet recent studies report a high recurrence rate of HCC after DAA; this calls availability of a reliable screening method to properly exclude HCC before DAA treatment.The primary objective of our cohort study was to assess the feasibility of an abbreviated MRI protocol as a screening tool for the detection of hepatic focal lesions/early HCC in patients with HCV-related liver cirrhosis.The study included 41 patients with HCV-related cirrhosis candidates to DAA therapy. All patients underwent routine screening for HCC by combined abdominal ultrasound and serum alfa-fetoprotein. An abbreviated MRI protocol (Abr-MR) including combined T2-weighted image and diffusion-weighted imaging (DWI) followed by dynamic contrast-enhanced MRI (CE-MRI) was performed for all subjects, assessing for presence and characterization of focal lesions.ResultsFor all included 41patients, no elevation of the alpha-fetoprotein was shown. Ultrasound detected a single focal lesion in one patient. Abbreviated MR demonstrated 15 focal lesions; for detected lesions, 1 lesion shows “shine though” and the rest showing moderate and high degrees of restriction. CE-MRI characterized lesions as 1 lesion = LIRADS-1, 3 lesions = LR-M, and 11 lesions = LR-5.The standard screening using combined ultrasound and alpha-fetoprotein had sensitivity, specificity, PPV, and NPV of 6.6 % (95% CI = 0.0034–0.29), 100% (95% CI = 0.89–1.000), 100% (95% CI = 0.051–1.000), and 68.8% (95% CI = 0.54–0.80). Abr-MR protocol showed sensitivity, specificity, PPV, and NPV of 100% for all parameters (95% CI = 0.79–1.000, 0.89–1.000, 0.79–1.000, and 0.89–1.000 respectively).ConclusionIn our study, we demonstrate the superiority of a proposed cost-effective Abr-MR protocol in the detection of hepatic focal lesions and small-sized HCC compared to routine screening using alpha-fetoprotein and ultrasound in HCV-related liver cirrhosis.
Highlights
Chronic hepatitis C virus (HCV) infection is a global health problem causing progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)
For the Abr-Magnetic resonance imaging (MRI), a total of 15 focal lesions were detected on either T2WI/T2-SPIR or diffusion-weighted imaging (DWI) in 10 patients
Adding the DWI/Apparent diffusion coefficient (ADC) into the proposed abbreviated MRI protocol (Abr-MR) protocol for detection of focal lesions increased sensitivity and Negative predictive value (NPV) for 100% retaining specificity and positive predictive value at 100%
Summary
Chronic HCV infection is a global health problem causing progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The primary objective of our cohort study was to assess the feasibility of an abbreviated MRI protocol as a screening tool for the detection of hepatic focal lesions/early HCC in patients with HCV-related liver cirrhosis. Chronic HCV infection is a global health problem that affects millions of people worldwide. In patients with chronic HCV infection, progressive hepatic fibrosis leading to cirrhosis (in 15–35% of patients after 25–30 years duration) is responsible for most of HCV-related morbidity and mortality, including hepatocellular carcinoma (HCC) [1]. The risk of HCC in HCV-infected people was tenfold higher compared to HCV-negative individuals, and risk estimates of 20–25fold have been reported in case-control studies. The interval from infection to HCC has been estimated to be 30 years, latent periods of 40–50 years have been observed [2]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Egyptian Journal of Radiology and Nuclear Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
